Digital Health Tools clinical trials

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

This study looks at a new drug (Trastuzumab Deruxtecan, T-DXd) for advanced HER2-positive breast cancer that has spread. It combines this drug with Pertuzumab and uses phone apps and devices to help manage side effects and detect problems early.